SCHEMBL4767156

SCHEMBL4767156

CCCOc1ccc2ccccc2c1C1=CC=CO[C]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.40
CNR2 P34972 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX5 P09917 1/20 0.38
PLA2G1B P04054 1/20 0.37
HSP90AA1 P07900 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.36
HTR1B P28222 5/20 0.36
HTR1D P28221 1/20 0.35
SLC6A4 P31645 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720025 0.94 GAA (0.47) CNR1CNR2GAATDP1L3MBTL1
SCHEMBL4724055 0.90 ALOX5 (0.47) TSHRTDP1ALOX5MAPT
SCHEMBL4767263 0.83 MAPT (0.57) MEN1KMT2AMAPTCYP2C9CYP1A2
SCHEMBL2048172 0.78 MAPT (0.58) CNR1CNR2MEN1KMT2ATSHR
SCHEMBL4722144 0.77 CYP1A2 (0.39) MEN1KMT2AMAPTCYP2C9CYP1A2
SCHEMBL8881796 0.72 GAA (0.59) CNR1CNR2MEN1KMT2AGAA
SCHEMBL4724303 0.72 CNR1 (0.39) CNR1CNR2MEN1KMT2ATSHR
SCHEMBL18878606 0.72 CNR1 (0.51) CNR1CNR2MEN1KMT2ATSHR
SCHEMBL4723498 0.71 MEN1 (0.44) CNR1CNR2MEN1KMT2ATSHR
SCHEMBL14331323 0.71 GAA (0.65) CNR1CNR2GAATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CNR1 318/4885CNR2 385/4885MEN1 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.